Literature DB >> 20838369

Complications with recombinant human bone morphogenic protein-2 in posterolateral spine fusion: a consecutive series of 1037 cases.

Steven D Glassman1, Jennifer Howard, John Dimar, Alexander Sweet, Greg Wilson, Leah Carreon.   

Abstract

STUDY
DESIGN: Retrospective case series.
OBJECTIVE: The purpose of this study was to report on a large consecutive series of posterolateral fusion cases using rhBMP-2/ACS. SUMMARY OF BACKGROUND DATA: Despite evidence that rhBMP-2/ACS is effective as an iliac crest graft substitute in posterolateral fusion, concerns remain regarding potential risk for BMP use in clinical practice. These concerns have been fueled by the serious complications reported with BMP in anterior cervical spine fusion. While none of the literature on posterolateral fusion with rhBMP-2/ACS has suggested an increased complication rate versus iliac crest bone graft, this issue has not been specifically studied.
METHODS: We reviewed medical records for a consecutive series of 1037 patients who underwent posterolateral spine fusion using rhBMP-2 between 2003 and 2006. Medical complications were attributed to the surgical procedure if they occurred within the 3-month perioperative period, whereas complications potentially related to BMP were included regardless of time frame.
RESULTS: Medical and surgical complications were observed in 190 of 1037 patients (18.3%) with 81 major complications (7.8%) and 110 minor complications (10.2%). Neurologic complications were related to screw malposition in 6 patients and epidural hematoma in 3 patients. New or more severe postoperative radicular symptoms were noted in 7 patients (0.7%). Psoas hematoma was identified by CT scan in 8 patients (0.8%). Complications directly related to rhBMP-2 were observed in at least 1 patient (0.1%) and in a worst case analysis, in as many as 6 patients (0.6%).
CONCLUSION: This study in 1037 patients confirms the relative safety of rhBMP-2/ACS for posterolateral spine fusion. There were extremely few complications directly attributed to rhBMP-2/ACS, and the overall complication rates were consistent with established norms. The stark contrast between this experience and the markedly elevated complication rate reported with anterior cervical BMP usage emphasizes the need to evaluate risks and benefits of bioactive technologies in a site-specific and procedure-specific manner.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20838369     DOI: 10.1097/BRS.0b013e3181d133d0

Source DB:  PubMed          Journal:  Spine (Phila Pa 1976)        ISSN: 0362-2436            Impact factor:   3.468


  27 in total

1.  Effect of Bone Powder/Mesenchymal Stem Cell/BMP2/Fibrin Glue on Osteogenesis in a Mastoid Obliteration Model.

Authors:  Chul Ho Jang; Gwang Won Cho; An-Ji Song
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

Review 2.  What's new in spine surgery.

Authors:  Keith H Bridwell; Paul A Anderson; Scott D Boden; Alexander R Vaccaro; Jeffrey C Wang
Journal:  J Bone Joint Surg Am       Date:  2011-08-17       Impact factor: 5.284

3.  Trends analysis of rhBMP utilization in single-level posterior lumbar fusion (PLF) in the United States.

Authors:  Lifeng Lao; Jeremiah R Cohen; Elizabeth L Lord; Zorica Buser; Jeffrey C Wang
Journal:  Eur Spine J       Date:  2015-05-24       Impact factor: 3.134

Review 4.  Regulation of bone and cartilage by adenosine signaling.

Authors:  Lauren C Strazzulla; Bruce N Cronstein
Journal:  Purinergic Signal       Date:  2016-07-29       Impact factor: 3.765

5.  Effects of low dose FGF-2 and BMP-2 on healing of calvarial defects in old mice.

Authors:  Lyndon F Charles; Jessica L Woodman; Daisuke Ueno; Gloria Gronowicz; Marja M Hurley; Liisa T Kuhn
Journal:  Exp Gerontol       Date:  2015-02-12       Impact factor: 4.032

6.  Lumbar interbody fusion with utilization of recombinant human bone morphogenetic protein: a retrospective real-life study about 277 patients.

Authors:  Stéphane Litrico; Tristan Langlais; Florent Pennes; Antoine Gennari; Philippe Paquis
Journal:  Neurosurg Rev       Date:  2017-03-10       Impact factor: 3.042

7.  Fusion and subsidence rate of stand alone anterior lumbar interbody fusion using PEEK cage with recombinant human bone morphogenetic protein-2.

Authors:  Eyal Behrbalk; Ofir Uri; Ruth M Parks; Rachel Musson; Reuben Chee Cheong Soh; Bronek Maximilian Boszczyk
Journal:  Eur Spine J       Date:  2013-08-19       Impact factor: 3.134

8.  Synthetic bone mimetic matrix-mediated in situ bone tissue formation through host cell recruitment.

Authors:  Yu-Ru Shih; Ameya Phadke; Tomonori Yamaguchi; Heemin Kang; Nozomu Inoue; Koichi Masuda; Shyni Varghese
Journal:  Acta Biomater       Date:  2015-03-21       Impact factor: 8.947

9.  pHEMA-nHA encapsulation and delivery of vancomycin and rhBMP-2 enhances its role as a bone graft substitute.

Authors:  Xinning Li; Jianwen Xu; Tera M Filion; David C Ayers; Jie Song
Journal:  Clin Orthop Relat Res       Date:  2013-08       Impact factor: 4.176

10.  FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension.

Authors:  Edda Spiekerkoetter; Xuefei Tian; Jie Cai; Rachel K Hopper; Deepti Sudheendra; Caiyun G Li; Nesrine El-Bizri; Hirofumi Sawada; Roxanna Haghighat; Roshelle Chan; Leila Haghighat; Vinicio de Jesus Perez; Lingli Wang; Sushma Reddy; Mingming Zhao; Daniel Bernstein; David E Solow-Cordero; Philip A Beachy; Thomas J Wandless; Peter Ten Dijke; Marlene Rabinovitch
Journal:  J Clin Invest       Date:  2013-07-15       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.